Int J Clin Pharm Th
-
Int J Clin Pharm Th · May 2002
Randomized Controlled Trial Clinical TrialPharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
To assess the pharmacokinetics, safety and tolerability of dexloxiglumide, a new CCK1 receptor antagonist currently under development for the treatment of the constipation-predominant irritable bowel syndrome. ⋯ The safety and pharmacokinetic profile of dexloxiglumide when the drug is administered as single and repeated doses in the dose range 100 - 400 mg provides the rationale for the choice of the treatment schedule (200 mg t.i.d.) for the efficacy trials in patients with (constipation-predominant) irritable bowel syndrome.